Trump's reciprocal tariffs would hit these European Union products that Americans buy the hardest
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...
RiverBender.com8d
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
AOL15d
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
A new painkiller has been approved for the first time in 25 years — and there's no risk of addiction, experts say. On Thursday, Jan. 30, The U.S. Food and Drug Administration announced that it ...
Insider Monkey15d
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s About The Scripts, Not About The Pill’
In this article, we are going to take a look at where Eli Lilly ... Mounjaro and Zepbound weekly scripts are finally, finally doing good. And they have been not good. . . .” “Lilly versus ...
Forbes17d
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest Approval
The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...
Nasdaq18d
What Does the Future Hold for Eli Lilly?
With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.